Hormone- And HER2-receptor Assessment in 33,046 Breast Cancer Patients: A Nationwide Comparison of Positivity Rates Between Pathology Laboratories in the Netherlands

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-019-05180-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Variation in Rates of Oestrogen Receptor Positivity in Breast Cancer Again

BMJ
2002English

Quality Assessment of HER2 Testing by Monitoring of Positivity Rates

Virchows Archiv
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2011English

Comparison of HER2 and Phospho-Her2 Expression Between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method

PLoS ONE
Multidisciplinary
2013English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Reproducibility in the Assessment of HER2 DISH in Breast Cancer

The Bangkok Medical Journal
2015English

Loss of HER2 Positivity After Anti-Her2 Chemotherapy in HER2-positive Gastric Cancer Patients: Results of the GASTric Cancer HER2 Reassessment Study 3 (GASTHER3)

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2018English

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

PLoS ONE
Multidisciplinary
2018English

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy